Dashboard
Manage Tickers

APREAprea Therapeutics, Inc.

Nasdaq atrinpharma.com


$ 3.48 $ -0.06 (-1.72 %)    

Friday, 16-Aug-2024 14:09:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.01 $ 0.89 (0.18 %)
DIA $ 408.70 $ -0.53 (-0.13 %)
SPY $ 560.23 $ 0.30 (0.05 %)
TLT $ 98.67 $ -0.01 (-0.01 %)
GLD $ 231.60 $ -0.06 (-0.03 %)
$ 3.72
-- x --
-- x --
-- - --
$ 3.20 - $ 8.85
655
na
22.09M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-15-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-16-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-27-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wedbush-reiterates-outperform-on-aprea-therapeutics-maintains-11-price-target
Wedbush Reiterates Outperform on Aprea The...
08/13/2024 14:34:10

Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $11 price target.

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
08/12/2024 17:50:04

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-q2-eps-058-beats-064-estimate-sales-56157k-beat-5000k-estimate
Aprea Therapeutics Q2 EPS $(0.58) Beats $(...
08/12/2024 12:41:23

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
06/24/2024 17:34:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-to-host-virtual-kol-event-on-june-24-2024-to-discuss-apr-1051-a-selective-oral-wee1-inhibitor
Aprea Therapeutics To Host Virtual KOL Eve...
06/21/2024 12:12:20

Features Medicinal Chemistry Expert Joseph Vacca And University Of Pennsylvania's Eric J. Brown Discussing Preclinical Find...

aprea-therapeutics-to-host-virtual-kol-event-on-apr-1051
Aprea Therapeutics To Host Virtual KOL Eve...
06/21/2024 12:11:46

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
06/17/2024 14:43:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-doses-first-patient-in-phase-1-acesot-1051-study-of-oral-wee1-inhibitor-apr-1051-as-monotherapy-for-advanced-solid-tumors
Aprea Therapeutics Doses First Patient In ...
06/17/2024 12:34:35

aprea-therapeutics-safety-review-committee-endorses-dosing-patients-with-atrn-119-in-aboya-119-clinical-trial
Aprea Therapeutics Safety Review Committee...
05/28/2024 12:48:46

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose ...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
05/14/2024 15:15:35

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-q1-eps-067-beats-078-estimate-sales-38057k
Aprea Therapeutics Q1 EPS $(0.67) Beats $(...
05/14/2024 12:47:24

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(...

aprea-therapeutics-announces-presentations-on-its-next-generation-wee1-inhibitor-apr-1051-and-a-novel-macrocyclic-atr-inhibitor-atrn-119-at-aacr-annual-meeting-2024
Aprea Therapeutics Announces Presentations...
04/10/2024 16:02:28

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/04/2024 12:09:11

wedbush-maintains-outperform-on-aprea-therapeutics-raises-price-target-to-11
Wedbush Maintains Outperform on Aprea Ther...
03/27/2024 11:54:52

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and raises the price target fro...

hc-wainwright--co-maintains-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Maintains Buy on Aprea...
03/26/2024 15:12:14

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pri...

aprea-therapeutics-q4-earnings-insights
Aprea Therapeutics: Q4 Earnings Insights
03/26/2024 13:10:10

why-is-precision-oncology-focused-aprea-therapeutics-stock-trading-higher-on-monday
Why Is Precision Oncology-Focused Aprea Th...
03/11/2024 13:39:22

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/11/2024 13:05:55

Core News & Articles
Market-Moving News for March 11th
03/11/2024 12:40:56

DUO: 151% | Fangdd Network shares are trading higher after the company announced its 2024 strategic layout with plans to enter ...

aprea-therapeutics-shares-are-trading-higher-after-the-company-announced-fda-clearance-of-its-ind-for-apr-1051-the-company-also-announced-private-placement-financing-of-up-to-34-million
Aprea Therapeutics shares are trading high...
03/11/2024 12:38:35

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION